Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial

ConclusionIn the Chinese population, lasmiditan was better than placebo for both primary endpoints and key secondary endpoints with an acceptable safety profile. No new safety signals were detected in the Chinese population. These findings are generally consistent with those observed in the CENTURION study published data and the established product profile.Trial Registration NumberNCT03670810.

http://link.springer.com/10.1007/s40120-022-00369-1

Source: Neurology and Therapy - June 17, 2022 Category: Neurology Source Type: research